Contact this trialFirst, we need to learn more about you.
TEAD Inhibitor
TEAD Inhibitor for Solid Cancers
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing IK-930, a new oral medicine, in patients with advanced solid tumors who have no other effective treatments. The medicine aims to block a protein that helps cancer cells grow.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service